Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. The gene discussed is VEGFA; the disease is hereditary clear cell renal cell carcinoma.